Cargando…

Clinical utility of risedronate in postmenopausal osteoporosis: patient considerations with delayed-release formulation

Bisphosphonates are the most widely prescribed treatment for postmenopausal osteoporosis, secondary osteoporosis, and male osteoporosis. Notwithstanding their high effectiveness and favorable safety profile, the adherence to bisphosphonate treatment remains low. Different treatment strategies aim to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kinov, Plamen, Boyanov, Mihail
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3333827/ https://www.ncbi.nlm.nih.gov/pubmed/22532780 http://dx.doi.org/10.2147/IJWH.S18209

Ejemplares similares

Once-monthly risedronate for postmenopausal osteoporosis
por: Casadei, Kristina, et al.
Publicado: (2010)

Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years
por: McClung, M. R., et al.
Publicado: (2012)

Risedronate’s Role in Reducing Hip Fracture in Postmenopausal Women with Established Osteoporosis
por: Gates, Brian J., et al.
Publicado: (2012)

Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis
por: Moro-Álvarez, María J, et al.
Publicado: (2008)

Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis
por: Rackoff, Paula
Publicado: (2009)

Anti-fracture Efficacy of Monthly Risedronate Compared with That of Weekly Risedronate in Postmenopausal Korean Women with Osteoporosis: A Nationwide Cohort Study
por: Cho, Yong Ho, et al.
Publicado: (2020)

Cost-effectiveness of teriparatide compared with alendronate and risedronate for the treatment of postmenopausal osteoporosis patients in Iran
por: Ebadi Fard Azar, Amir Ali, et al.
Publicado: (2017)

Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France
por: Hiligsmann, M., et al.
Publicado: (2019)

Review of the safety and efficacy of risedronate for the treatment of male osteoporosis
por: Bobba, Raja, et al.
Publicado: (2007)

A Novel Monthly Dosing Regimen of Risedronate for the Treatment of Postmenopausal Osteoporosis: 2-Year Data
por: McClung, Michael R., et al.
Publicado: (2012)

Baseline Characteristics and Changes in Bone Mineral Density T-Scores of Bulgarian Women with Postmenopausal Osteoporosis Receiving Denosumab in Routine Clinical Practice
por: Boyanov, Mihail, et al.
Publicado: (2016)

Clinical Management of Women with Newly Diagnosed Osteoporosis: Data from Everyday Practice in Bulgaria
por: Boyanov, Mihail A., et al.
Publicado: (2021)

Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA
por: Eisman, John A., et al.
Publicado: (2023)

Effects of risedronate on fracture risk in postmenopausal women with osteopenia
por: Siris, E. S., et al.
Publicado: (2007)

Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data
por: McClung, M. R., et al.
Publicado: (2012)

Optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations
por: Sunyecz, John
Publicado: (2008)

Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: post-hoc analysis of data from the risedronate phase III clinical trials
por: Shigematsu, Takashi, et al.
Publicado: (2017)

Reducing hip fracture risk with risedronate in elderly women with established osteoporosis
por: Masud, Tahir, et al.
Publicado: (2009)

Development of clinical utility of zoledronic acid and patient considerations in the treatment of osteoporosis
por: Ringe, Johann D
Publicado: (2010)

Cost–effectiveness of weekly gastro-resistant risedronate 35 mg, compared with weekly alendronate 70 mg tablets, in the treatment of postmenopausal osteoporosis in Spain
por: Casado, Enrique, et al.
Publicado: (2023)

Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet
por: McClung, M. R., et al.
Publicado: (2011)

Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates
por: Petranova, T., et al.
Publicado: (2017)

The Therapeutic Effectiveness of the Coadministration of Weekly Risedronate and Proton Pump Inhibitor in Osteoporosis Treatment
por: Tanaka, Mizue, et al.
Publicado: (2014)

Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass
por: Hamdy, Ronald C
Publicado: (2010)

Effects of Risedronate on Osteoarthritis of the Knee
por: Iwamoto, Jun, et al.
Publicado: (2010)

An open‐label randomized study of the relative absorption of gastro‐resistant risedronate taken fasted or with food versus immediate‐release risedronate
por: Kleinermans, Diane, et al.
Publicado: (2022)

Use of risedronate for consolidation and callus formation in Colles fractures in postmenopausal women: SOLID study
por: Oliveira, Lindomar Guimarães, et al.
Publicado: (2015)

Botanicals in Postmenopausal Osteoporosis
por: Słupski, Wojciech, et al.
Publicado: (2021)

Polymorphisms of the human IL-1 receptor antagonist gene and forearm bone mineral density in postmenopausal women
por: Ivanova, Jivka T., et al.
Publicado: (2012)

Treatment options for postmenopausal osteoporosis
por: Walsh, Garry M
Publicado: (2012)

Bazedoxifene for the prevention of postmenopausal osteoporosis
por: Gennari, Luigi, et al.
Publicado: (2008)

Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain
por: Darbà, Josep, et al.
Publicado: (2015)

Effects of teriparatide compared with risedronate in the treatment of osteoporosis: A meta-analysis of randomized controlled trials
por: Yang, Chengzhi, et al.
Publicado: (2020)

Enhancing Osteoporosis Treatment through Targeted Nanoparticle Delivery of Risedronate: In Vivo Evaluation and Bioavailability Enhancement
por: Saifi, Zoya, et al.
Publicado: (2023)

A 3-year postmarketing study on the safety and effectiveness of once-monthly risedronate in Japanese patients with osteoporosis
por: Soen, Satoshi, et al.
Publicado: (2020)

The utility of clinical decision tools for diagnosing osteoporosis in postmenopausal women with rheumatoid arthritis
por: Brand, Caroline, et al.
Publicado: (2008)

Postmenopausal Osteoporosis
por: Kamel, Hosem K.
Publicado: (2006)

Intravenous bisphosphonates for postmenopausal osteoporosis
por: Mottaghi, Peyman
Publicado: (2010)

Efficacy and safety of bazedoxifene for postmenopausal osteoporosis
por: Kawate, Hisaya, et al.
Publicado: (2011)

Profile of teriparatide in the management of postmenopausal osteoporosis
por: Sikon, Andrea, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_91glioi2b4u2rq3jtfejpjpkk5